OTCMKTS:IDXG Interpace Biosciences (IDXG) Stock Price, News & Analysis $1.61 +0.04 (+2.55%) As of 03:03 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsBuy This Stock About Interpace Biosciences Stock (OTCMKTS:IDXG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Interpace Biosciences alerts:Sign Up Key Stats Today's Range$1.58▼$1.6350-Day Range$1.44▼$1.7052-Week Range$0.77▼$2.40Volume29,804 shsAverage Volume7,219 shsMarket Capitalization$7.13 millionP/E Ratio20.13Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Read More Interpace Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreIDXG MarketRank™: Interpace Biosciences scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Interpace Biosciences. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Interpace Biosciences is 20.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.57.Price to Earnings Ratio vs. SectorThe P/E ratio of Interpace Biosciences is 20.13, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 269.18.Price to Book Value per Share RatioInterpace Biosciences has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Interpace Biosciences has been sold short.Short Interest Ratio / Days to CoverInterpace Biosciences has a short interest ratio ("days to cover") of 0.12, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Interpace Biosciences has recently increased by 3.74%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInterpace Biosciences does not currently pay a dividend.Dividend GrowthInterpace Biosciences does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.78 News SentimentInterpace Biosciences has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Interpace Biosciences this week, compared to 1 article on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Interpace Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders0.93% of the stock of Interpace Biosciences is held by insiders.Percentage Held by Institutions5.73% of the stock of Interpace Biosciences is held by institutions.Read more about Interpace Biosciences' insider trading history. Receive IDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDXG Stock News HeadlinesTapdi Oksijen Publishes 2026 Mid-Year Consolidated Activity ReportAugust 18 at 12:11 PM | tipranks.comTapdi Oksijen’s Profit Slides Despite Asset Growth and Rising LeverageAugust 18 at 12:11 PM | tipranks.comSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing total outflows to 14 billion. At the same time, the World Gold Council recorded the highest quarterly central bank gold buying on record, with buyers taking physical delivery instead of paper shares.August 20 at 1:00 AM | Behind the Markets (Ad)Tapdi Oksijen Confirms Accuracy of First-Half 2026 Consolidated FinancialsAugust 18 at 12:11 PM | tipranks.comTapdi Oksijen Publishes TSRS‑Aligned 2025 Sustainability ReportAugust 18 at 12:11 PM | tipranks.comPDI's 16%+ Yield: Despite 7 Big Risks, 5 Clever Ways PIMCO May Defend ItAugust 15, 2026 | seekingalpha.comCan Retirees Trust PDI’s 15.8% Monthly Payout? PIMCO’s Premium Problem, ExplainedAugust 13, 2026 | 247wallst.comSPDI Extends AdvEn Loans and Clears Related-Party Deal for Planned AIM TransactionAugust 11, 2026 | tipranks.comSee More Headlines IDXG Stock Analysis - Frequently Asked Questions How have IDXG shares performed this year? Interpace Biosciences' stock was trading at $1.2302 at the beginning of 2026. Since then, IDXG stock has increased by 30.9% and is now trading at $1.61. How were Interpace Biosciences' earnings last quarter? Interpace Biosciences, Inc. (OTCMKTS:IDXG) released its earnings results on Monday, August, 10th. The business services provider reported $0.01 earnings per share (EPS) for the quarter. The business services provider had revenue of $9.13 million for the quarter. Interpace Biosciences had a trailing twelve-month return on equity of 145.40% and a net margin of 67.64%. How do I buy shares of Interpace Biosciences? Shares of IDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Interpace Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Bristol Myers Squibb (BMY), Novavax (NVAX) and Histogenics (HSGX). Company Calendar Last Earnings8/10/2026Today8/20/2026AGM 20268/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolOTCMKTS:IDXG CIK1054102 Webwww.interpace.com Phone855-776-6419Fax862-207-7820Employees152Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.08 Trailing P/E Ratio20.13 Forward P/E RatioN/A P/E GrowthN/ANet Income$24.58 million Net Margins67.64% Pretax Margin11.06% Return on Equity145.40% Return on Assets87.36% Debt Debt-to-Equity RatioN/A Current Ratio2.22 Quick Ratio2.22 Sales & Book Value Annual Sales$38.73 million Price / Sales0.18 Cash Flow$5.96 per share Price / Cash Flow0.27 Book Value$5.25 per share Price / Book0.31Miscellaneous Outstanding Shares4,430,000Free Float4,388,000Market Cap$7.13 million OptionableNot Optionable Beta0.61 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:IDXG) was last updated on 8/20/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredLook at this $5 stock’s addressA small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...Freedom Financial | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredAnthropic Just Became the First Trillion-Dollar Private CompanyAnthropic is now worth more than a trillion dollars, making it the first private company to reach that milesto...Weiss Ratings | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
